ArticleACS nano medicine2026
Intrathecal Delivery of Macromolecules to the Spinal Cord Enabled by Laser-Activated Perfluorocarbon Nanodroplets.
Article in ACS nano medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The lack of safe, minimally invasive strategies for targeted drug delivery to the spinal cord remains a major barrier to treating neurodegenerative disease and spinal injury. Intrathecally administered macromolecules, including gene therapy vectors, rarely penetrate spinal tissue at therapeutically relevant concentrations due to cellular barriers at the cerebrospinal fluid-spinal cord interface. Here, we demonstrate the application of laser-activated perfluorocarbon nanodroplets (PFCnDs) for nonsurgical, spatially controlled delivery from the subarachnoid space into spinal cord parenchyma. Following intrathecal injection in rats, transdermal laser irradiation produced a 7-fold increase in photoacoustic signal within the spinal cord parenchyma compared to nonirradiated controls, confirming spatially selective intraparenchymal nanodroplet delivery. Codelivery of 500 kDa FITC-dextran demonstrated approximately 1 mm penetration into the dorsal horn at irradiated sites, while nonirradiated regions showed only superficial perivascular accumulation. Neither nanodroplets alone nor laser irradiation alone produced intraparenchymal delivery, indicating that vaporization-induced cavitation is necessary for penetration. The PFCnDs (∼300 nm diameter) were engineered with a lipid shell, perfluorohexane core, and near-infrared absorbing dye for transdermal activation at 1064 nm. These results demonstrate that laser-activated nanodroplets can deliver macromolecular cargo into the spinal cord via lumbar puncture and transdermal irradiation, without surgical exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.